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The protein-tyrosine kinase Pyk2/CAK/CADTK is a
key activator of Src in many cells. At hippocampal syn-
apses, induction of long term potentiation requires the
Pyk2/Src signaling pathway, which up-regulates the ac-
tivity of N-methyl-D-aspartate-type glutamate receptors.
Because localization of protein kinases close to their
substrates is crucial for effective phosphorylation, we
investigated how Pyk2 might be recruited to the
N-methyl-D-aspartate receptor complex. This interac-
tion is mediated by PSD-95 and its homolog SAP102.
Both proteins colocalize with Pyk2 at postsynaptic den-
dritic spines in the cerebral cortex. The proline-rich
regions in the C-terminal half of Pyk2 bind to the SH3
domain of PSD-95 and SAP102. The SH3 and guanylate
kinase homology (GK) domain of PSD-95 and SAP102
interact intramolecularly, but the physiological signifi-
cance of this interaction has been unclear. We show that
Pyk2 effectively binds to the Src homology 3 (SH3) do-
main of SAP102 only when the GK domain is removed
from the SH3 domain. Characterization of PSD-95 and
SAP102 as adaptor proteins for Pyk2 fills a critical gap
in the understanding of the spatial organization of the
Pyk2-Src signaling pathway at the postsynaptic site and
reveals a physiological function of the intramolecular
SH3-GK domain interaction in SAP102.
At low stimulus frequency, synaptic transmission depends
largely upon -amino-3-hydroxy-5-methylisoxazole-4-propionic
acid (AMPA)1-type glutamate receptors (1, 2). High frequency
stimulation promotes Ca2 influx through N-methyl-D-aspar-
tate (NMDA) receptors, thereby inducing long term potentia-
tion (LTP) (1, 3, 4). LTP is a lasting increase in synaptic
transmission that may underlie learning and memory (5, 6).
NMDA receptors likely consist of one or two NR1 and two or
three NR2 subunits; each subunit has an extracellular N ter-
minus and an intracellular C terminus (7–10). The very C
termini of NR2 subunits interact with the first two PDZ do-
mains of PSD-95/SAP90 and the related proteins SAP102 and
PSD-93/chapsyn110. PSD-95 and its homologs (SAP102, PSD-
93, and SAP97) are scaffolding proteins consisting of three PDZ
domains, one SH3 domain, and one GK domain. PSD-95, PSD-
93, and SAP102 are thought to be involved in clustering glu-
tamate receptors together with other proteins at postsynaptic
sites (11–15). SAP97 interacts with the AMPA receptor subunit
GluR1 (16–18). SAP97 colocalizes with GluR1, but not
GluR2/3, at postsynaptic sites (17). This interaction may al-
ready occur early in the secretory pathway and may be involved
in trafficking or targeting of AMPA receptors (19).
SH3 and GK domains of PSD-95 and its homologs form
intramolecular and, to some degree, intermolecular interac-
tions (20–24). A point mutation in the Drosophila protein Dlg
(a homolog of PSD-95) results in the substitution of a conserved
leucine in the SH3 domain to a proline; this mutation leads to
the loss of septate junction formation and overproliferation of
the imaginal disc (25). Replacing the homologous leucine (Leu-
460) with a proline in the SH3 domain of PSD-95 inhibits the
interaction of the mutant SH3 domain with the GK domain (20,
22). Collectively these findings indicate the physiological im-
portance of the SH3-GK domain interaction, but a molecular
function of this interaction remains to be established.
Tyrosine phosphorylation of NR2B (26, 27) is augmented on
LTP induction (28, 29), and several observations suggest that
up-regulation of NMDA receptor activity by Src-mediated ty-
rosine phosphorylation is an important step in the induction of
LTP. 1) Src increases NMDA receptor activity (30–32) by ele-
vating its peak current (33), 2) the activity of Src is up-regu-
lated during LTP (34), 3) inhibition of Src can prevent LTP (30),
and 4) an increase in synaptic transmission on Src activation
occludes subsequent LTP induction (34).
It is well established that Src can be activated by another
tyrosine kinase, Pyk2/CAK/CADTK (35–38). Pyk2 is stimu-
lated upon Ca2 influx, activation of PKC by phorbol esters, or
stimulation of Gq-linked receptors such as the muscarinic ace-
tylcholine receptor M1 or the metabotropic glutamate receptor
mGluR1 (35, 37, 39–48). Neither Ca2 nor PKC appear to
directly regulate Pyk2 in vitro (39); how Ca2 or PKC activates
Pyk2 in vivo is unknown. When stimulated, Pyk2 autophospho-
rylates itself on tyrosine 402. The SH2 domain of Src binds to
this phosphorylated tyrosine of Pyk2, resulting in activation of
Src (35, 36). Recent evidence indicates that similar to Src, Pyk2
is necessary for the induction of LTP, likely because it in-
creases the activity of Src (49).
Precise localization of protein kinases is a critical require-
ment for fast and specific signaling via phosphorylation of a
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variety of substrates (50–52). For example, efficient regulation
of AMPA receptors requires that PKA be localized in close
proximity to protein kinase A anchor proteins (53). Similarly,
Ca2-calmodulin-dependent protein kinase II is recruited to
the postsynaptic site via multiple, highly regulated interac-
tions with the NMDA receptor (54–58). We now show that
Pyk2 binds to PSD-95 and SAP102 in the NMDA receptor
complex, which also contains Src. More specifically, the proline-
rich region in the C-terminal half of Pyk2 directly interacts
with the SH3 domains of PSD-95 and SAP102. This binding is
inhibited by the intramolecular interaction of the GK domain
with the SH3 domain in SAP102 by regulating Pyk2 binding to
the SH3 domain.
EXPERIMENTAL PROCEDURES
Materials—Glutathione-Sepharose was purchased from Amersham
Biosciences and protein A-Sepharose from Sigma. Antibodies against
Pyk2 and pcDNA3 plasmids for the expression of hemagglutinin-tagged
full-length rat Pyk2 and FLAG-tagged human CRNK (residues 692–
1009 of Pyk2) (59, 60) in HEK293 cells were generously provided by
Drs. L. M. Graves and H. S. Earp (University of North Carolina, Chapel
Hill). We also purchased monoclonal antibodies against the C terminus
of Pyk2 from BD Transduction Laboratories. Mammalian pCMV ex-
pression vectors of Myc-tagged full-length rat PSD-95 and rat SAP102
and bacterial expression vectors for the production of GST fusion pro-
teins containing the PDZ1-3 (residues 57–405), PDZ2 (residues 156–
248), and GK (residues 534–723) domains of PSD-95 and the SH3-GK
domains (residues 537–647) of SAP102 (13, 61, 62) were graciously
supplied by Dr. C. C. Garner (Stanford University, Palo Alto, CA), and
plasmids for the production of GST fusion proteins of the PDZ3 (resi-
dues 302–402; originally in pGAD; subcloned into the EcoRI site of
pGEX4T-1) and SH3 (residues 431–500) domains of PSD-95 were gra-
ciously supplied by Dr. M. Sheng (Howard Hughes Medical Institute,
Massachusetts Institute of Technology, Boston) (63, 64). Expression
vectors for GST-CRNK (residues 671–1009 in pGEX2TK) and GST-N-
CRNK (residues 876–1009) were generously made available by Drs. T.
Sasaki (Sapporo Medical University, Sapporo, Japan), and M. D.
Schaller (University of North Carolina, Chapel Hill). Other reagents
were of standard biochemical quality and from established providers.
Immunoprecipitation and Immunoblotting—Crude membrane frac-
tions were prepared from rat forebrain as described (65). NMDA recep-
tor complexes were extracted either directly from hippocampal tissue or
from membrane fractions with deoxycholate (1%) at 0–4 °C (18, 55, 65).
In some experiments membrane fractions were solubilized with 1% SDS
for 30 min at 60 °C. This SDS extraction protocol dissociates the NMDA
receptor complex and subsequently allows the specific immunoprecipi-
tation of individual subunits after neutralization of SDS by excess
Triton X-100 (18, 55, 65). Immunoprecipitation and immunoblotting
were performed as described (18, 65) with antibodies against NR1-,
NR2A-, NR2B-, and NR2A/B (18, 65), PSD-95 (residues 494–510 (66)),
SAP102 (residues 21–119 (66)), Src (monoclonal antibody 327 (67)), and
portions of the N- and the C-terminal half of Pyk2 (the antibodies
Pyk2-N and Pyk2-C were produced by immunizing rabbits with GST
fusion proteins encompassing residues 1–80 and 680–860, respectively,
as described (68)). The specificities of the antibodies have been carefully
characterized (17, 18, 65–68). Chromatographically purified nonspecific
mouse or rabbit IgGs (Zymed Laboratories Inc.) were used for control
immunoprecipitations to test for nonspecific interactions of proteins
with antibodies.
Transient Expression of Pyk2, CRNK, PSD-95, and SAP102 in
HEK293 Cells—HEK293 fibroblasts were plated at 20–30% and main-
tained at 50–90% confluency in Dulbecco’s modified Eagle’s medium
(Invitrogen), containing 10% heat-inactivated fetal bovine serum (No-
vaTech), 2 mM L-glutamine, and 1 mM sodium pyruvate. HEK293 cells
were transiently transfected following a modified (69) calcium phos-
phate precipitation protocol (70) with pCMV-PSD-95 or -SAP102 and
pcDNA3-Pyk2 or -CRNK expression constructs. To enhance transfec-
tion efficiency, an equimolar amount of pAdVantage (Promega) was
present during each transfection (71). Cells were collected 24–48 h
post-transfection and lysed with RIPA buffer (10% glycerol, 1% Nonidet
P-40, 0.4% deoxycholate, 150 mM NaCl, 5 mM EGTA, 5 mM EDTA in 50
mM Tris, pH 7.4) or 1% Triton X-100 in 25 mM Tris-Cl, pH 7.4, 150 mM
NaCl, 5 mM EDTA, 5 mM EGTA. Both lysis buffers contained pepstatin
A (1 g/ml), leupeptin (10 g/ml), aprotinin (20 g/ml), and phenyl-
methanesulfonyl fluoride (200 nM). Lysates were cleared by ultracen-
trifugation and used for either immunoprecipitation or pull-down ex-
periments with GST fusion proteins.
Expression Constructs for GST Fusion Proteins of the SH3 and GK
Domains of SAP102—A vector for expressing GST-SH3 fusion protein
carrying residues 537–647 of rat SAP102 was produced by removing
the GK domain from the original SAP102 GST-SH3-GK vector (a mod-
ified pGEX2T vector (13)) with NdeI and EcoRI. Overhangs were filled
in with Klenow fragment, followed by blunt-end ligation. Positive clones
were identified by colony PCR. The vector for expressing the GST-GK
fusion protein covering residues 658–837 of full-length SAP102 was
obtained through amplification of the GK domain by PCR using primers
containing EcoRI restriction sites (5primer, 5 CAA GAA GAA TTC
TAT GCC AGG CCT GTG ATC ATC TTG G 3; 3primer, 5 CCA AAT
GAA TTC TCA AGA CTG GTC CTC AAT GAT TTG TTT G 3). The PCR
product was digested with EcoRI and inserted into EcoRI-digested
pGEX4T-1 vector before transformation into Escherichia coli. Clones
containing pGEX4T-1 vectors with the GK domain inserted in the
correct orientation were identified by colony PCR. All new and old
vectors used in this study were confirmed by DNA sequencing.
Interaction Assays with GST Fusion Proteins—GST and GST fusion
proteins of the PDZ1-3, PDZ2, PDZ3, SH3, and GK domains of PSD-95
or SH3, GK, and SH3-GK domains of SAP102, along with CRNK and
N-CRNK, were expressed from pGEX vectors (13) in the E. coli strain
BL21 (Novagen) as described (18). Equal amounts of the different GST
fusion proteins or GST (25 g) were absorbed onto glutathione-Sepha-
rose (20 l), and the residues were incubated for 2 h at 4 °C with
lysates (prepared with RIPA buffer) from HEK293 cells transiently
overexpressing Pyk2, CRNK, PSD-95, or SAP102. Typically, the ali-
quots of the HEK293 lysates contained 300 g of total protein as
determined with the BCA assay (Pierce). Resins were washed with 500
mM NaCl, 10 mM Tris-Cl, pH 7.4, with 0.1% Triton X-100 in TBS (150
mM NaCl, 10 mM Tris-Cl, pH 7.4) and with TBS alone and then analyzed
by immunoblotting as described (18, 55). Lysate containing 5–10 g of
protein was loaded onto gels as a positive control. Pyk2 was detected in
these experiments with an antibody against the C-terminal portion of
the kinase (residues 833–997; purchased from BD Transduction Labo-
ratories). The presence of equal amounts of the GST fusion proteins was
routinely verified by Ponceau S staining (Sigma) or probing with an
anti-GST antibody (18).
Immunofluorescence—Four male Sprague-Dawley rats (200–350 g;
Charles River) were deeply anesthetized with sodium pentobarbital (60
mg/kg intraperitoneally), and intracardially perfused with heparinized
saline followed by freshly depolymerized 0.5% paraformaldehyde in
phosphate buffer (PB, 0.1 M, pH 7.4). Coronal 50-m sections were cut
on a Vibratome and collected in cold PB. For single immunofluores-
cence, sections were incubated overnight in antibody to Pyk2 (1:1,000).
Immunoreactivity was then visualized by donkey anti-rabbit conju-
gated to fluorescein isothiocyanate (FITC; Jackson ImmunoResearch).
Because Pyk2, SAP102, and NR2A/B antibodies were raised in rabbit,
tyramide signal amplification (TSA) was used for one of them, and
subsequent conventional fluorescent staining was used for one of the
other antibodies for double-labeling (72–74). After preincubation in 10%
normal donkey serum, sections were incubated with Pyk2 antiserum at
a dilution not recognized by a conventional fluorochrome-conjugated
secondary antibody (1:20,000) and then reacted with biotinylated sec-
ondary antibody. Biotin was localized by a FITC-TSA direct kit
(PerkinElmer Life Sciences). After preincubation in 1% normal donkey
serum, SAP102 antiserum (1:1,000; Chemicon) or NR2 antiserum (1:
1,000; Chemicon) was applied overnight. Immunoreactivity was visual-
ized with donkey anti-rabbit antibody, conjugated to CY-3 (Jackson
ImmunoResearch). Sections were then processed for synaptophysin
(1:1,000; Clone SVP-38; Sigma) or PSD-95 (1:1,000; Clone 16; Trans-
duction Laboratories). After overnight incubation in primary antibody,
immunoreactivity was visualized with donkey anti-mouse antibody con-
jugated to Cy-5 (Jackson ImmunoResearch). Control sections were pro-
cessed as above, except that primary or secondary antibodies were
omitted or replaced by nonspecific control antisera. To control for pos-
sible cross-reaction between the first primary antibody and the second
secondary antibody, tissue was processed as above, except that the
second primary antibody was omitted. Omission of primary or second-
ary antibodies eliminated specific labeling. Furthermore, consistent
results were obtained after reversing the first and the second primary
antibodies, using first SAP102 or NR2 (1:20,000) with FITC-TSA and
then Pyk2 (1:1,000) with Cy-3-conjugated secondary antibody.
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RESULTS
Coimmunoprecipitation of Pyk2 and Src with NMDA Recep-
tors—Because kinases are often localized in close proximity to
their targets, we hypothesized that kinases involved in tyrosine
phosphorylation of the NMDA receptor may be associated with
this receptor. In fact, an earlier report (31) suggests that Src,
which can up-regulate NMDA receptor activity, binds to the
NMDA receptor complex. To test whether Pyk2, an activator of
Src, associates with the NMDA receptor complex, rat forebrain
samples were solubilized with deoxycholate and used for im-
munoprecipitations with antibodies against NR2A and -2B.
Previously, we showed (18, 55, 65) that the interactions be-
tween the NMDA receptor and its associated proteins including
PSD-95, SAP102, and Ca2-calmodulin-dependent protein ki-
nase II are well preserved under these conditions. Subsequent
immunoblotting revealed that Pyk2 specifically and reproduc-
ibly coprecipitated with the NMDA receptor complex (Fig. 1A).
We also observed copurification of Src with the Pyk2-NMDA
receptor complex, especially if a mixture of NR2A and 2B
antibodies was used for immunoprecipitation of the NMDA
receptor (Fig. 1B). Coprecipitation of Pyk2 and Src with the
NMDA receptor was specific because precipitations with non-
immune control antibodies did not result in isolation of Pyk2
or Src.
Coimmunoprecipitation of Pyk2 with PSD-95 and SAP102—
PSD-95 and its homologs SAP102 and PSD-93 mediate the
association of the NMDA receptor with various signaling pro-
teins including neuronal nitric-oxide synthase and Ras-activat-
ing SynGAP (75–77). Therefore, we tested whether Pyk2 might
be associated with PSD-95 or SAP102. Immunoprecipitation
with antibodies against SAP102 resulted in coprecipitation of
Pyk2 as detected with the antibody against the N-terminal 80
residues of Pyk2 (Pyk2-N; Fig. 2A, lanes 6 and 7). Probing of
total membrane extract with the Pyk2-N antibody demon-
strated the specificity of this antibody for Pyk2, which pos-
sesses a molecular mass of about 115 kDa (lane 1). Immuno-
precipitation with both Pyk2-N and Pyk2-C also yielded the
115-kDa polypeptide that is immunoreactive for Pyk2-N (lanes
3 and 4, respectively). Pyk2 copurified with PSD-95 (lane 11),
as well. To test whether Pyk2 might bind to SAP102 or PSD-95
after extraction with detergents rather than being associated
with those two proteins in vivo, we solubilized brain mem-
FIG. 1. Pyk2 is associated with the NMDA receptor complex.
NMDA receptor complexes were extracted with 1% deoxycholate from
rat hippocampal tissue, and immunoprecipitations (IP) were per-
formed with antibodies against NR2A (A, lanes 1 and 2), NR2B (A,
lanes 5 and 6), a mixture of antibodies against NR2A and -2B (B,
lanes 1 and 2), or non-immune control antibodies (A, lanes 3 and 7, B,
lane 3). Immunoblots of these samples were cut, and the portions
comprising the range around 200 kDa were probed with antibodies
against NR2A (lanes 1–4 in A and B), or an antibody that recognizes
NR2A and -2B (A, lanes 5–7). The portions surrounding the range
around 120 and 60 kDa were incubated with the Pyk2-N antibody (A
and B) and the antibody against Src (B), respectively (indicated on
the left and right side of each blot). For comparison, 20 l of extract
was also directly applied to SDS-PAGE. Specific coprecipitations of
Pyk2 and Src with the NMDA receptor precipitations are shown in
duplicate to document reproducibility of the coprecipitations and
were performed several times with similar results.
FIG. 2. Coimmunoprecipitation of
Pyk2 with PSD-95 and SAP102 from
rat brain. Rat forebrain membrane frac-
tions were extracted with 1% deoxy-
cholate on ice or, when indicated, with
SDS at 60 °C (dissociated; A, lanes 8, 9,
and 13) and used for immunoprecipita-
tions (antibodies are indicated at the bot-
tom of each blot) and subsequent immu-
noblotting. NR2A/B and Control indicate
immunoprecipitations (IP) with a mixture
of antibodies against NR2A and -2B and
with nonspecific control IgG, respectively.
20 l of extract were also directly applied
to SDS-PAGE when indicated (Extract).
Blots were probed with antibodies against
Pyk2-N (68) (A) or SAP102 (B). Similar
results were obtained in several other
experiments.
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branes with 1% SDS at 60 °C and subsequently added an
excess of Triton X-100, which forms mixed micelles with SDS,
thereby neutralizing it. This treatment dissociates the different
components of the NMDA receptor complex including PSD-95
and SAP102 (9, 55, 62, 65). Under these conditions Pyk2 did
not coprecipitate with either SAP102 (lanes 8 and 9) or PSD-95
(lane 13). These observations indicate that the interactions
between Pyk2 and PSD-95 or SAP102 do not form during the
extraction procedure and are likely to occur in vivo. These
interactions were further confirmed by immunoprecipitation of
Pyk2 with either Pyk2-N or Pyk2-C and subsequent detection
of SAP102 (Fig. 2B) and PSD-95 (data not shown) in immuno-
complexes by immunoblotting.
Pyk2 Interacts with PSD-95 and SAP102 in HEK293 Cells in
the Absence of the NMDA Receptor—To evaluate whether the
association between Pyk2 and PSD-95 or SAP102 depends on
the presence of the NMDA receptor or is due to a direct inter-
action, we expressed Pyk2 with either PSD-95 or SAP102 in the
heterologous HEK293 cell line. Immunoprecipitation of Pyk2
with either Pyk2-N or Pyk2-C from cell lysates resulted in
coprecipitation of PSD-95 and SAP102 (Fig. 3, upper panels).
The specificities of these coprecipitations were demonstrated
by the lack of PSD-95 and SAP102 immunoreactivity in immu-
noprecipitations with control IgG. Because HEK293 cells are
non-neuronal and do not express NMDA receptors, these re-
sults suggest that Pyk2 interaction with PSD-95 and SAP102
does not require the NMDA receptor and might be direct.
Colocalization of Pyk2 with SAP102 and PSD-95—Multiple
immunofluorescence staining was performed to compare the
cellular and subcellular distribution of Pyk2 with that of
FIG. 3. Pyk2 interacts with PSD-95 and SAP102 in HEK293
cells. Pyk2 was transiently expressed in HEK293 cells together with
either PSD-95 or SAP102. HEK293 cells were solubilized with RIPA
buffer. Immunoprecipitations (IP) were performed with the Pyk2-N and
the Pyk2-C antibody (68) and with non-immune rabbit IgG (Control).
PSD-95 and SAP102 were detected by immunoblotting with the corre-
sponding antibodies (upper panels). Blots were stripped and reprobed
with Pyk2-N to confirm the presence of Pyk2 and the specificity of the
immunoprecipitations (lower panels). Two other experiments yielded
similar results.
FIG. 4. Pyk2 colocalizes with SAP102 at subcellular sites including synapses and postsynaptic spines in rat forebrain. A–C, confocal
immunofluorescence images of immunostaining with the Pyk2-N antibody in the cerebral cortex. A, low magnification view showing numerous
stained neurons in cortical layer III. B, higher magnification view from layer V. Both pyramidal (arrows) and nonpyramidal neurons (arrowheads)
were immunopositive. Staining was prominent in somata and proximal dendrites, especially in apical dendritic shafts of pyramidal neurons. C,
Pyk2 immunoreactivity was also observed in many spines (arrowheads) and puncta in nearby neuropil. D–F, confocal images showing colocaliza-
tion of Pyk2 (FITC, green) with SAP102 (Cy-3, red). D, low magnification view of cortical layer III. Nearly all cells immunoreactive for Pyk2 were
also immunoreactive for SAP102. Likewise, in the neuropil, colocalization of Pyk2 and SAP102 was frequently observed (arrowheads). E, high
magnification view of a spiny dendrite immunoreactive for both Pyk2 and SAP102. Many spines positive for Pyk2 were also positive for SAP102
(arrowheads). F, enlargement of area boxed in E; arrowheads point to double-labeled spines and arrows to double-labeled puncta, likely to
correspond to synapses, as defined by their association with synaptophysin (Syn., Cy-5, blue). Scale bars: A, 50 m; B, 20 m; C, 5 m; D, 50 m;
E, 5 m; and F, 3 m.
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SAP102 and PSD-95. Pyk2 antibodies stained a population of
neurons distributed throughout the cerebral cortex (Fig. 4).
Some of these neurons can be identified as pyramidal neurons
(Fig. 4B, arrows); others were non-pyramidal cells of various
shapes and sizes (Fig. 4B, arrowheads). Staining was typically
patchy within dendrites and somatic cytoplasm, excluding the
nucleus. At higher magnification, Pyk2 immunoreactivity was
obvious in many dendritic spines (Fig. 4C). Numerous Pyk2
immunoreactive puncta were observed throughout the neuropil
(Fig. 4D1, arrowheads). Such a distribution pattern often re-
flects a synaptic distribution. Double labeling with the presyn-
aptic marker synaptophysin confirmed that many of the Pyk2-
positive puncta were at synaptic sites (e.g. see Fig. 4F, 1, 3, and
4, arrows).
SAP102-immunopositive neurons were also widely distrib-
uted in the cerebral cortex in a pattern that matched Pyk2
staining (Fig. 4D2). Double labeling confirmed that almost all
SAP102-positive neurons were also positive for Pyk2 and vice
versa (Fig. 4D3). In the neuropil, punctate colocalization was
prominent (Fig. 4D3, arrowheads). Many of these puncta are
likely to be synapses as indicated by double labeling with
synaptophysin (e.g. Fig. 4, F2–4, arrows). Furthermore, Pyk2
and SAP102 immunoreactivity codistributed along dendrites,
concentrating at dendritic spines (Fig. 4E1) juxtaposed to pre-
synaptic synaptophysin staining (Fig. 4F). These results indi-
cate that Pyk2 and SAP102 are colocalized not only in neuronal
somata and dendrites but also at postsynaptic sites, where they
may be associated with NMDA receptors.
NR2 and PSD-95 antibodies stained a large population of
pyramidal and non-pyramidal neurons throughout the cortex.
Triple immunofluorescence labeling showed cellular colocaliza-
tion of Pyk2 with NR2 and PSD-95 (Fig. 5). This distribution
was patchy in somata and proximal dendrites; some of these
patches exhibited all three antigens, but others were immu-
nopositive only for NR2 (Fig. 5, lower right). In the neuropil,
most Pyk2-positive puncta colocalized with NR2 and PSD-95
staining. Likewise, Pyk2-positive spines were also triple-la-
beled (Fig. 5, arrowheads in insets). However, many PSD-95
and some NR2-positive puncta were negative for Pyk2. These
findings indicate that Pyk2 is colocalized with PSD-95 and
NMDA receptors at many, although perhaps not all, postsyn-
aptic spines where these proteins might be associated with
each other.
The Proline-rich Region of Pyk2 Binds to the SH3 Domain of
PSD-95—To define the interaction site of Pyk2 in PSD-95, we
expressed GST fusion proteins of the PDZ1-3, PDZ2, PDZ3,
SH3, and GK domains of PSD-95 in E. coli. Equal amounts of
these fusion proteins were immobilized on glutathione-Sepha-
rose, washed, and incubated with cell lysates of transfected
HEK293 cells that ectopically expressed Pyk2, after lysates
were pre-cleared with GST alone. Subsequent immunoblotting
demonstrated that Pyk2 specifically bound to the SH3 domain
of PSD-95 (Fig. 6A) and SAP102 (Fig. 6B). We obtained the
same results when brain extracts were used as a source of
native Pyk2 in similar pull-down experiments (data not
shown). Immunoblots were stained with Ponceau S (Fig. 6,
lower panels) and re-probed with anti-GST antibodies (not
shown) to ensure that comparable amounts of each GST fusion
protein were present in the various samples.
Pyk2 contains two segments that are proline-rich and con-
stitute potential interaction sites for SH3 domains. These seg-
ments are toward the C terminus of Pyk2 (residues 713–720
and 855–862). We used the C-terminal Pyk2 fragment span-
ning residues 671–1009 for interaction assays. This fragment
included the two proline-rich regions together with flanking
sequences on both ends. It lacked the N-terminal region of
Pyk2, which contains a homologous band 4.1 domain and the
central catalytic domain. This catalytically inactive fragment,
called CRNK (CADTK or CAK-related non-kinase) or Pyk2-
related non-kinase, is expressed as a truncated version of Pyk2
in brain and other tissues (59, 78, 79). Analogous to a similar
C-terminal fragment of the related focal adhesion kinase FAK,
which is also expressed in vivo and inhibits certain functions of
FAK (80–82), CRNK is thought to interfere with those signal-
FIG. 5. Subcellular and synaptic co-
localization of Pyk2 with PSD-95 and
NR2 subunits in the cerebral cortex.
Confocal immunofluorescence images
showing colocalization of Pyk2 (Pyk2-N
antibody; FITC, green) with NR2 (Cy-3,
red), and PSD-95 (Cy-5, blue). Arrows
point to two triple-labeled pyramidal neu-
rons in layer V. In the neuropil, most
Pyk2-positive puncta are also positive for
NR2 and PSD-95. However, many PSD-
95-positive and some NR2-positive
puncta are negative for Pyk2. Insets show
an enlargement of the boxed area. Pyk2-
positive dots colocalize with NR2 and
PSD-95 immunoreactivity (arrows); ar-
rowheads point to spines immunopositive
for all three proteins. Scale bars, 20 m;
insets, 3 m.
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ing mechanisms of Pyk2 that depend on the interaction of the
C-terminal domain of Pyk2 with corresponding binding part-
ners (59, 78, 79). It is, therefore, not only of biochemical but
also of physiological interest to determine whether the SH3
domain of PSD-95 binds to CRNK. Like Pyk2, we expressed
CRNK in HEK293 cells and used lysates of these cells for
pull-down experiments with the PSD-95 derived GST-SH3 fu-
sion protein. CRNK bound to this fusion protein but not to GST
alone (Fig. 6B) indicating a specific interaction with the SH3
domain of PSD-95.
To test whether the proline-rich segments of Pyk2 are re-
sponsible for PSD-95 and SAP102 binding, we expressed GST
fusion proteins of CRNK (residues 671–1009) and N-CRNK
(residues 876–1009, lacking the two proline-rich segments) as
GST fusion proteins. Lysates of HEK293 cells ectopically ex-
pressing full-length PSD-95 or SAP102 were used for pull-down
experiments with GST fusion proteins of CRNK, N-CRNK,
and the SH3 and GK domains of PSD-95 or SAP102. CRNK but
not N-CRNK specifically interacted with full-length PSD-95
and SAP102 in these in vitro binding assays (Fig. 7). These
results indicate that the proline-rich segments mediate the
Pyk2-PSD-95 interaction. We consistently observed much
weaker binding of SAP102 to CRNK than PSD-95 and there-
fore analyzed the availability of the SH3 domains in full-length
PSD-95 and SAP102 for binding. Biochemical and crystallo-
graphic studies demonstrated that the SH3 and GK domains of
PSD-95 and its homologs form intramolecular interactions
(20–24). Intermolecular binding of the SH3 domain of one
FIG. 6. Interaction of the SH3 domain of PSD-95 and SAP102 with the C-terminal region of Pyk2. GST and the GST fusion proteins
given at the bottom of each panel were expressed in E. coli, adsorbed onto glutathione-Sepharose, and incubated with RIPA buffer lysates from
HEK293 cells transiently overexpressing Pyk2 (A and B) or its truncated version, CRNK (C). After washing, samples were analyzed by
immunoblotting. Cell extract (Lysate) containing 5 g of protein was used as positive control. Probing blots with an antibody against the C-terminal
portion of Pyk2 (upper panels) demonstrated that Pyk2 specifically bound to the SH3 domain of PSD-95 (A) and SAP102 (B). This Pyk2 antibody
was from Transduction Laboratories and recognizes full-length Pyk2 (A and B) as well as CRNK (C) but does not cross-react with the GST moiety
of our fusion proteins (in contrast to the Pyk2-N and Pyk2-C antibodies, which had been produced against GST fusion proteins of the corresponding
Pyk2 regions (68)). Binding to PSD-95 was mediated by the C-terminal region of Pyk2 (CRNK; C). Blots were stained with Ponceau S (lower panels)
before blocking and probing to show that comparable amounts of GST fusion proteins were present on each resin sample. Similar results were
obtained in several other experiments.
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PSD-95 molecule with the GK domain of another PSD-95 mol-
ecule can occur, but the intramolecular interaction is favored
and occludes exogenous SH3 from binding to the GK domain
and vice versa. The GST-SH3 and GST-GK fusion proteins
specifically bound full-length PSD-95 on a weak basis, suggest-
ing that, under our conditions, there is some access for the SH3
domain to its binding site on the GK domain, and vice versa, in
full-length PSD-95. The interaction of GST-SH3 with SAP102
was weaker, and binding of GST-GK to SAP102 was not de-
tectable. These results raise the possibility that the intermo-
lecular interaction between the SH3 and GK domains of
SAP102 may limit the interaction between Pyk2 and the SH3
domain.
Intramolecular GK Domain Association with the SH3 Do-
main Inhibits Pyk2 Binding—To test whether the presence of
the GK domain within the same polypeptide influences the
interaction of the SH3 domain of SAP102 with Pyk2, we per-
formed pull-down experiments with GST fusion proteins car-
rying the SH3 or GK domain separately or in tandem. Whereas
the GST fusion protein carrying only the SH3 domain of
SAP102 pulled down Pyk2 from HEK293 cell lysates, a similar
amount of a GST fusion protein with the combined SH3-GK
domain did not (Fig. 8). The GK domain by itself did not
mediate precipitation of Pyk2 in these pull-down experiments.
These experiments indicate that SAP102 binds via its SH3
domain to Pyk2 and that the GK domain can inhibit this
interaction.
DISCUSSION
Our results indicate that Pyk2, like Src, is associated with
the NMDA receptor complex (Fig. 1) via the SH3 domains of
PSD-95 and SAP102. The Pyk2 interaction with PSD-95 and
SAP102 appears to be rather stable, as it can be detected after
immunoprecipitation from brain (Fig. 2), a procedure that
takes several hours, and also from HEK293 cells ectopically
expressing these proteins (Fig. 3). Re-association does not ap-
pear to play a role during these immunoprecipitations; after
dissociation of the Pyk2-PSD-95 and Pyk2-SAP102 complexes
with SDS and neutralization of SDS with Triton X-100, Pyk2
does not rebind to PSD-95 or SAP102 (Fig. 2). An in vivo
interaction of Pyk2 with PSD-95 and SAP102 is further sup-
ported by our immunofluorescence microscopy studies. Pyk2
colocalizes with SAP102 and PSD-95 at synapses, which were
identified by triple labeling with the presynaptic marker pro-
tein synaptophysin (Fig. 4) or with antibodies against the
NR2A and -2B subunits of the NMDA receptor complex (Fig. 5).
Pyk2 did not interact with the different PDZ domains of
PSD-95 in pull-down experiments (Fig. 6), consistent with the
FIG. 8. Inhibition of Pyk2 binding to the SH3 domain of
SAP102 by an intramolecular SH3-GK domain interaction. GST
and the GST fusion proteins indicated at the bottom of the panels were
adsorbed onto glutathione-Sepharose, incubated with RIPA buffer ly-
sates of HEK293 cells transiently overexpressing Pyk2, and analyzed
by immunoblotting with an antibody against the C-terminal portion of
Pyk2 (Transduction Laboratories; upper panel). Cell extract (Lysate, 5
g of protein) was used as positive control. Pyk2 only bound to the
isolated SH3 domain of SAP102 but not to the GST fusion protein
carrying the combined SH3-GK domains. Ponceau S staining (lower
panels) detected similar amounts of GST fusion proteins in each resin
sample. Similar results were obtained in several other experiments.
FIG. 7. Requirement of the proline-rich region of Pyk2 for binding to PSD-95 and SAP102. GST and the GST fusion proteins outlined
at the bottom of the panels (CRNK, residues 671–1009; N-CRNK, residues 876–1009 of Pyk2) were adsorbed onto glutathione-Sepharose,
incubated with 1% Triton X-100 lysates of HEK293 cells transiently overexpressing Myc-tagged PSD-95 (left) or SAP102 (right), and analyzed by
immunoblotting with anti-Myc antibody (upper panels). Cell extract (Lysate, 10 g of protein) was loaded as positive control. CRNK specifically
interacted with PSD-95 and SAP102 only when the proline-rich region was present (FL-CRNK). Consistently less SAP102 than PSD-95 was pulled
down by either CRNK or the respective SAP102 SH3 domain. Blots were stained with Ponceau S (lower panels) before probing to confirm that equal
amounts of GST fusion proteins were present. Results were replicated in several additional experiments.
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fact that the C terminus of Pyk2 (Pro-Pro-Ala-Glu) does not
conform to a classic PDZ domain binding motif. Rather, it
specifically bound to the SH3 domains of PSD-95 and SAP102.
An 300-residue-long C-terminal fragment of full-length Pyk2
containing two proline-rich regions (713–720 and 855–862)
was sufficient for binding to the SH3 domain. This portion of
Pyk2, known as CRNK, is expressed in parallel with full-length
Pyk2 in several tissues including brain (59, 78, 79), similar to
the homologous fragment FAK-related non-kinase of the re-
lated focal adhesion kinase FAK (80–82). Signaling pathways
that depend on the interaction of the C-terminal domain of
Pyk2 with corresponding binding partners can be inhibited by
CRNK (59, 78, 79). Therefore, CRNK may regulate the Pyk2
interaction with PSD-95 and SAP102 and thereby the effi-
ciency of NMDA receptor regulation by Pyk2. In support of this
speculation, the dominant negative Pyk2 mutant K457A (35,
39) prevents up-regulation of NMDA receptor peak currents by
endogenous Pyk2 (49), suggesting the mutant blocks access of
the endogenous wild-type Pyk2 to the SH3 domains of PSD-95
and SAP102 in the NMDA receptor complex.
Only a few binding partners for the SH3 domain of PSD-95
and its homologs have been identified, including the KA2 sub-
unit of the kainate-type glutamate receptor (83), A kinase
anchor protein 150 (84), and huntingtin (85). In addition to
these interactions, the SH3 and GK domains of PSD-95 and its
homologs can undergo intramolecular and, to some extent,
intermolecular interactions (20–24). Mutations that disrupt
this intramolecular association in the PSD-95 homolog Dlg
result in overproliferation of the imaginal disc in Drosophila
(25). These observations suggest that the regulation of protein-
protein interactions between the SH3 and GK domains has a
critical function in vivo. Recent experiments indicate that dis-
ruption of the SH3-GK domain interaction interferes with the
channel clustering activity of PSD-95 (22); however, the precise
mechanism underlying this phenomenon is unclear.
The linker domain between the SH3 and GK domain has
been implicated as a potential binding site for ligands that
might induce conformational changes of the SH3-GK module
(21, 86, 87). This region is also involved in targeting Dlg to
septate junctions in epithelial cells (88) and to synapses at the
neuromuscular junction (89) of Drosophila. Our present results
indicate that the SH3 domain of SAP102, and perhaps also
PSD-95, primarily binds Pyk2 when the SH3 domain is not
engaged in an intramolecular interaction with the GK domain.
We hypothesize that specific regulatory mechanisms, such as
association of the GK or linker domain with a binding partner
or a post-translational modification, like phosphorylation of
SAP102 and PSD-95, control the SH3-GK interaction and,
thereby, Pyk2 binding to the SH3 domain.
Several PKC phosphorylation sites have been identified on
the NMDA receptor (65, 90–92) that influence receptor func-
tion. For example, phosphorylation of the C1 cassette of the
NR1 C terminus may regulate the distribution of the NMDA
receptor on the cell surface (91, 93). In addition, stimulation of
PKC generally results in up-regulation of NMDA receptor ac-
tivity (94–99). However, recent findings suggest that potenti-
ation of NMDA receptors is not always due to direct phospho-
rylation of the receptor subunits by PKC (100). Elegant work by
MacDonald and co-workers (33, 49) demonstrated that Pyk2
and Src act downstream of PKC to increase NMDA receptor
activity. Earlier studies indicated that NR2A and -2B are phos-
phorylated on tyrosine residues in vivo (26, 27, 46, 101) and
that NMDA receptor activity is up-regulated by Src (30–
32,102). Furthermore, the increase in NMDA receptor activity
by PKC was prevented by specific inhibitors of Src (33). These
observations suggest that intermediary kinases, such as Pyk2
and Src, are involved in the PKC signaling cascade resulting
in the phosphorylation of the NMDA receptor. This model is
supported by coimmunoprecipitation of Src and the NMDA
receptor (Fig. 1; see also Ref. 34) reflecting the formation of a
Src-NMDA receptor complex for efficient and specific phos-
phorylation of the receptor. However, additional experiments
are necessary to characterize further the interaction between
Src and the NMDA receptor and the phosphorylation of NR2A
and -2B by Src.
How does PKC control Src activity? Stimulation of PKC by
phorbol esters or Gq-coupled receptors results in activation of
Pyk2 (35, 38, 39, 46). Up-regulation of NMDA receptor activity
by PKC can be inhibited by injection of a purified, dominant
negative Pyk2 mutant into hippocampal pyramidal neurons
(49). Furthermore, injection of purified wild-type Pyk2 in-
creases NMDA receptor currents, and this effect is blocked by
inhibition of Src. In contrast, the Src-mediated increase in
NMDA receptor activity (31–33) is not antagonized by domi-
nant negative Pyk2 (49). These results place PKC upstream of
Pyk2 and Src downstream of Pyk2 in that signaling pathway
(49). Because the induction of NMDA receptor-dependent LTP
requires Src (34) and Pyk2 (49), we hypothesize that LTP may
depend on the coassembly of Pyk2 and Src at the NMDA
receptor. Because Ca2 influx also leads to the activation of
Pyk2 independent of PKC stimulation (39, 46), anchoring of the
kinase at the NMDA receptor may place Pyk2 at a strategically
ideal location where NMDA receptor-mediated Ca2 influx into
the cytosol may most effectively contribute to Pyk2 activation.
As a result, Pyk2 autophosphorylation could lead to the asso-
ciation and activation of Src (35). However, it is yet unknown
how Ca2 influx or PKC activation induces Pyk2 activation
in vivo.
As an integral component of the NMDA receptor complex,
Pyk2 plays a critical role in the regulation of NMDA receptor
activity and function (Fig. 1) (49). We demonstrated that Pyk2
binds to the SH3 domain of PSD-95 and SAP102 and that the
interaction of Pyk2 with the SH3 domain is inhibited by the GK
domain. Our biochemical studies indicate a functional role of
the SH3-GK domain interaction in PSD-95 homologs, the reg-
ulation of Pyk2 binding. Our results will aid further studies
concerning the precise regulation of the NMDA receptor by
PKC, Pyk2, and Src signaling and the role of PSD-95 and its
homologs in synaptic functions that depend on the targeting of
these kinases.
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